DPP4 and breast carcinoma: Indeed, DPP4 inhibition using the anti-diabetes drug Sitagliptin has been associated with reduced incidence of breast cancer in diabetes patients [44], and has an immune-mediated protective effect in several preclinical models [38,45,46].